Details
Category: Volume 08 Issue 02 February 2020
Hits: 852

Title: Status of Care and Control among diabetic patients in Central Kashmir: A Cross-sectional Study

Author: Dr Zorawar Singh

 DOI: https://dx.doi.org/10.18535/jmscr/v8i2.157

Abstract

   

Background: Diabetes mellitus is one of those non-communicable diseases which has both immediate and delayed complications resulting in morbidity, high out of pocket costs, and high mortality rates. The objectives of our study was to assess the status of care and blood glucose control among patients with type 2 diabetic patients' in central Kashmir division.

Materials and Methods: This was a cross-sectional study done among 53 diagnosed cases of type 2 diabetes, mellitus. The sample was selected through multi-stage cluster random sampling and data was collected through a questionnaire by interviewing patients and reviewing their files, and 3 categories of demographic, clinical and socio-economic factors were studied. The data was analyzed by Chi-Square test using SPSS software version 20.

Results: The results of Chi-square test indicated that there is significant relationship between gender of the patients, increasing age among them, their marital status and level of education among them, while insignificant relationship was found for the occupation and family size of the diabetic patients. The results also showed significant relationship between body mass index, family history of diabetes, ordered drug use and nutritional education on diabetes. Socioeconomic characteristics of the studied samples regarding care and control showed significant relationship of smoking behavior and exercise with diabetes while insignificant results were concluded for vegetable consumption and income level.

Conclusion: We concluded that life style modifications, dietary modifications, control of weight gain and self-care programs are an effective medium for prevention of complication of diabetes mellitus.

Keywords: Diabetes Mellitus, Central Kashmir, Diabetes Care.

References

  1. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., ... & Simonson, D. C. (2015). Type 2 diabetes mellitus. Nature reviews Disease primers, 1, 15019.
  2. Lan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of Ethnopharmacology, 161, 69-81.
  3. Adjah, E. S. O., Ray, K. K., & Paul, S. K. (2018). Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk. Actadiabetologica, 1-10.
  4. Saleem SM, Jan SS, Haq I, Khan SMS. Identification of risk factors affecting impaired glucose metabolism among the adult population of district Srinagar. Diabetes Metab Syndr Clin Res Rev [Internet]. 2019;13(2):1047–51. Available from: https://doi.org/10.1016/j.dsx.2019.01.023
  5. Sheikh MS, Sheikh IS, Khan SMS, Mir S. Prevalence of type 2 diabetes mellitus among adult population of District Srinagar. Int J Diabetes Dev Ctries [Internet]. 2019; Available from: http://link.springer.com/10.1007/s13410-018-0704-4
  6. Gæde, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H., & Pedersen, O. (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine, 348(5), 383-393.
  7. Hodgson, J. M., Watts, G. F., Playford, D. A., Burke, V., & Croft, K. D. (2002). Coenzyme Q 10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European journal of clinical nutrition, 56(11), 1137.
  8. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ...& Steinberg, W. M. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322
  9. Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., ... & Cards Investigators. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentrerandomised placebo-controlled trial. The Lancet, 364(9435), 685-696.
  10. Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., Van Gaal, L. F., & RIO-Diabetes Study Group. (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. The Lancet, 368(9548), 1660-1672.
  11. Kemp, T. M., Barr, E. L., Zimmet, P. Z., Cameron, A. J., Welborn, T. A., Colagiuri, S., ... & Shaw, J. E. (2005). Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab. Diabetes care, 28(6), 1490-1492.
  12. Fosse-Edorh, S., Fagot-Campagna, A., Detournay, B., Bihan, H., Gautier, A., Dalichampt, M., &Druet, C. (2014). Type 2 diabetes prevalence, health status and quality of care among the North African immigrant population living in France. Diabetes & metabolism, 40(2), 143-150.
  13. Kumar, S. P., &Sandhya, A. M. (2018). A study on the glycemic, lipid and blood pressure control among the type 2 diabetes patients of north Kerala, India. Indian heart journal, 70(4), 482-485

Corresponding Author

Dr Zorawar Singh

Lecturer, Department of Pharmacology, Government Medical College, Srinagar